Member Info for EmeraldCarrots

Back to where it was IMHO, of course.

Back to where it was.

If he's a shareholder why did he "focus the market" via posts of what was already known? We ALREADY know the NHS has not got a shall we call it "general budget" for either of the two machines. We do know that might change. At the moment BOTH machines are financed through testing budgets or budgets from the individual NHS trusts. Are you telling me he did not know that? It's some sort of scam IMHO.

All IMHO.

Busicat.

I don't believe he has any shares. I don't trust him at all.

From medical machine suppliers looking to buy Genedrive Plc IMHO. No debt.

What's the betting he sold yesterday am and bought 1st thing today?

Then helps spook the market.

Up 15%

Similar to the MT-RNR1 to date. Self funding by trusts to start with etc........

Up 5.44%.

The progress with sales of the MT-RNR1 was/is more on my mind with the Scottish rollout starting in October.

The CYP2C19 is more in the testing phase as we know.

Today. My average is still around 2p. Orders from the NHS, rollout for NHS Scotland, sales to 7 other countries, no debt, FDA application........... £5m market cap. Get real!!!!!!!!!

More than people think? The chairman of the Company no less. Ever since I invested here his involvement has troubled me for some reason. Can't put my finger on why though. Maybe nothing. Having said that a huge amount of shareholder money has got the Company where it is. Now it seems it could be bought for next to nothing. By a wise investor with enough cash. Hmm. 2.5p a share please.

All IMHO.

Https://www.nice.org.uk/guidance/dg59/chapter/1-Recommendations

Point-of-care testing

1.4 Use the Genedrive CYP2C19 ID Kit point-of-care test for CYP2C19 genotype testing

*****when laboratory-based testing is not available*****.

Separate budget? This is the question.

In any event point of care test far more important than later test. May have budget priority or may be a separate budget.

Let's see what the RNS says 1st thing tomorrow.

I fancy the sp may be going back to 1p ish rather quickly.

All IMHO.

Https://www.nice.org.uk/guidance/dg59/chapter/1-Recommendations

Point-of-care testing

1.4 Use the Genedrive CYP2C19 ID Kit point-of-care test for CYP2C19 genotype testing when laboratory-based testing is not available.

Separate budget? Also point of care test far more important than later test.................

All IMHO.

Someone has engineered this sp fall and done a good job you have to say. The budget for the lab testing is under pressure as the emaoil says. If lab testing is not availiable then what do you do? Use the genedrive machine of course!!!!

LOL.

Waiting for the RNS to clarify.

All IMHO.

Bighammer.

You say they were also doing a pilot study for lab tests. The email, as I have pointed out is talking about lab testing:-

"commissioning decisions regarding further rollout of CYP2C19 testing via -----NHS Genomic Medicine Service laboratories-----.)

Interesting.

Do an alternative to lab testing. May be nothing to do with them. I'm sure they will clarify in an RNS 1st thing. The sp may be about to rocket back up. Depends what the RNS says.

It is unclear if it would affect Genedrive. It says:-

'We are aware that a number of services are keen to understand national timelines for commissioning decisions regarding further rollout of CYP2C19 testing ****via NHS Genomic Medicine Service laboratories****, prior to the use of clopidogrel following stroke in line with NICE guidance DG59.

It is referring to the budgets for laboratory testing. This may be nothing to do with Genedrive. This needs clarification.

"NHS England confirmed that information from the pilot has informed the implementation of routine commissioning and setting out an approach to national testing for the future remains a priority. However, within the current financial year, it has not been possible to identify the necessary recurrent headroom in revenue budgets to support the ***funding of this testing for the indicated population***. ". Eh? This is very unclear and needs clarification.

If this email is real it is extremely vague. Is it the laboratory budget they are referring to only? If so then it's irrelevant.

No doubt we will find out in an RNS 1st thing tomorrow morning from Genedrive who are probably working on it now.

'We are aware that a number of services are keen to understand national timelines for commissioning decisions regarding further rollout of CYP2C19 testing via ***NHS Genomic Medicine Service laboratories***, prior to the use of clopidogrel following stroke in line with NICE guidance DG59.